Karveer Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 4.93 Cr
- Company Age 19 Year, 8 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 14.74%
- Profit Growth 4.55%
- Ebitda -27.49%
- Net Worth 7.50%
- Total Assets 8.72%
About Karveer Pharma
Karveer Pharma Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 February 2006 and has a history of 19 years. Its registered office is in Ujlaiwadi, Kolhapur 416004, Maharashtra.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.93 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sharadchandra Diwan, Vivek Kadam, and Geetalee Joglekar serve as directors at the Company.
Company Details
- Location Ujlaiwadi, Kolhapur 416004, Maharashtra
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232PN2006PTC022014
- Company No.
022014
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Feb 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
What products or services does Karveer Pharma Private Limited offer?
Karveer Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine.
Who are the key members and board of directors at Karveer Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sharadchandra Diwan  | Director | 15-Feb-2006 | Current |
| Vivek Kadam | Director | 12-Jan-2021 | Current |
| Geetalee Joglekar | Director | 15-Feb-2006 | Current |
Financial Performance of Karveer Pharma.
Karveer Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 14.74% increase. The company also saw a slight improvement in profitability, with a 4.55% increase in profit. The company's net worth moved up by a moderate rise of 7.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Karveer Pharma?
Unlock access to Karveer Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Karveer Meditech Private LimitedVivek Kadam is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Karveer Pharma?
Unlock and access historical data on people associated with Karveer Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Karveer Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Karveer Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.